Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Prior laboratory-confirmed RSV infection.

Known or suspected HIV infection or impairment of immunological functions.

Receipt of immunosuppressive therapy, including any systemic, nasal, or inhaled corticosteroids within 28 days of enrollment. Note: Cutaneous (topical) steroid treatment is not an exclusion.

Any receipt of bone marrow/solid organ transplant.

Major congenital malformations (such as congenital cleft palate) or cytogenetic abnormalities.

Previous enrollment in this trial, previous pediatric receipt of a licensed or investigational RSV vaccine, or previous maternal or pediatric receipt of or planned administration of any other anti-RSV product (such as ribavirin or RSV IG or RSV monoclonal antibody \[mAb\]) within 4 months of screening or planned administration of an anti-RSV product between screening and day 56 after enrollment.

Any previous anaphylactic reaction.

Any known hypersensitivity to any study product component.

Heart disease. Note: Potential participants with cardiac abnormalities documented to be clinically insignificant and requiring no treatment may be enrolled.

Lung disease, including any history of reactive airway disease or medically diagnosed wheezing.

Member of a household that contains a person with chronic lung disease, including but not limited to chronic obstructive pulmonary disease (COPD), emphysema, or home oxygen use, reactive airway disease or asthma. Note: Asthma or reactive airway disease in a household member is not exclusionary unless the household member has taken oral steroids for asthma management in the past month and/or has been hospitalized for asthma in the past month.

Member of a household that contains, or will contain, an infant who is less than 4 months of age at the enrollment date through Day 14.

Member of a household that contains another child/other children who is/are enrolled or is/are scheduled to be enrolled in IMPAACT 2021 on a different date and has/have not completed the Day 56 visit in the same calendar year (i.e., all eligible children from the same household must be enrolled/receive study product on the same date or additional children in the household may be screened, enrolled, and randomized independently after other children in the household complete the Day 56 Visit).

Member of a household that contains another child who is, or is scheduled to be, enrolled in another study evaluating an intranasal live-attenuated RSV vaccine, AND there has been or will be an overlap in residency during Day 0 to 14 of that other child's participation in the study.

Member of a household that contains an immunocompromised individual, including, but not limited to:

* a person who has been diagnosed with cancer and who has received chemotherapy within the 12 months prior to enrollment; or

* a person living with a solid organ, cord blood, or bone marrow transplant.

Shares a daycare room with infants less than 4 months of age, and parent/guardian is unable or unwilling to suspend daycare for 14 days following study product administration.

Any of the following events at the time of enrollment:

* fever (rectal temperature of greater than or equal to 100.4°F (38°C)), or

* upper respiratory signs or symptoms (including but not limited to rhinorrhea, cough, or pharyngitis) or

* nasal congestion significant enough to interfere with successful study product administration, or

* otitis media.

* Note: if participant is randomized and subsequently noted to have any of the above, study product administration must be deferred per the study protocol.

Receipt of the following prior to enrollment (start counting backwards with '1' as the day of planned study product administration):

* any inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days prior, or

* any live vaccine, other than rotavirus vaccine, within the 28 days prior, or

* another investigational vaccine or investigational drug within 28 days prior. Note: if COVID-19 vaccine has EUA approval and ACIP recommendation for this age group, it is not considered investigational

Scheduled administration of the following after planned study product administration (start counting with '1' as the day of planned study product administration):

* inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days after, or

* any live vaccine other than rotavirus in the 28 days after, or

* another investigational vaccine or investigational drug in the 56 days after. Note: if COVID-19 vaccine has EUA approval and ACIP recommendation for this age group, it is not considered investigational.

Receipt of immunoglobulin, any antibody products, or any blood products within the past 6 months prior to enrollment

Receipt of any of the following medications within 3 days prior to study enrollment:

* systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis, or

* intranasal medications, or

* other prescription medication except as listed below

* Permitted concomitant medications (prescription or non-prescription) include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including (but not limited to) cutaneous (topical) steroids, topical antibiotics, and topical antifungal agents.

Born at less than 34 weeks gestation.

Born between 34 weeks gestation and 36 weeks and 6 days gestation and less than 1 year of age at the time of enrollment.

Current suspected or documented developmental disorder, delay, or other developmental problem.

Any previous receipt of supplemental oxygen therapy in a home setting.

Known or suspected SARS-CoV-2 exposure within the 14 days prior to enrollment. Note: known or suspected SARS-CoV-2 includes a known asymptomatic household member under quarantine for SARS-CoV-2 exposure but without a positive SARS-CoV-2 test.

What this study is about